CST1

Across TCGA pan-cancer cohorts, CST1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CST1 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CST1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CST1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, HNSC, and COAD are the cancer types where CST1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
HNSC	OS	Median	II,III,IV	0.165	0.716	<.001	42	view →
COAD	OS	Median	III,IV	0.140	0.792	<.001	27	view →
UCEC	DFS	Median	All	1.000	0.630	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CST1–ACC (DFS)

Open the ACC breakdown →